Glioblastoma immunotherapeutic SurVaxM studied at Norton Healthcare Brain Tumor Center

Norton Healthcare Brain Tumor Center researchers are conducting a clinical trial to determine whether immunotherapy drug SurVaxM improves survivability of glioblastoma.

Researchers at the Norton Healthcare Brain Tumor Center are conducting a clinical trial to determine whether a promising new immunotherapy drug, SurVaxM, improves survivability of glioblastoma.

SurVaxM targets survivin, a protein in 95% of glioblastomas and many other cancers. The immunotherapeutic is designed to trigger the patient’s immune system to attack cancer cells with survivin.

Kaylyn D. Sinicrope, M.D., neuro-oncologist with the Brain Tumor Center, is the local principal investigator on the phase 2 trial (NCT05163080), which is currently enrolling patients.

The trial is open to newly diagnosed glioblastoma patients. SurVaxM combined with standard-of-care temozolomide chemotherapy is compared with temozolomide treatment alone.

“We still have much to learn, but the early indications that SurVaxM can improve overall survival of newly diagnosed glioblastoma are exciting,” Dr. Sinicrope said. “This option is available now to patients who qualify.”

The study aims to discover what effects, both good and bad, the combination has on patients and whether SurVaxM can trigger the immune system to go after cancer cells.

In a previous study of 63 patients, survival nearly doubled compared to the standard of care.

The randomized, placebo-controlled study underway at the Brain Tumor Center will administer temozolomide plus shots of SurVaxM to some patients and the regular temozolomide regimen plus a shot of a placebo to others. Injections will be repeated at regular intervals.

The Norton Healthcare Brain Tumor Center is a collaboration of Norton Neuroscience Institute and Norton Cancer Institute.

Refer a patient

To refer a patient to the Norton Healthcare Brain Tumor Center for this or another clinical trial, visit Norton EpicLink and open an order for a Clinical Trial.

Refer online

Call (888) 4-U-Norton / (888) 486-6786

Current Brain Tumor Center clinical trials and studies

Get Our Monthly Newsletter

Stay informed on the latest offerings and treatments available at Norton Healthcare by subscribing to our monthly enewsletter.


Make a Referral

Partnering with you in caring for your patients.

Refer a Patient
Are You a Patient?
Provider Spotlight

Christopher P. Rhyne, M.D.

Christopher P. Rhyne, M.D., has joined Norton Neuroscience Institute as a headache medicine specialist.

Read More

Search our entire site.